Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
This article was originally published in The Tan Sheet
Executive Summary
The introduction of certain follow-on brand drugs as the original product nears patent expiration could raise anticompetitive concerns at the Federal Trade Commission, according to FTC Commissioner Pamela Harbour